相关实验视频

Updated: Jul 10, 2025

A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9

A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9

Published on: August 28, 2018

PCSK9抑制剂:脂质控制中的现状和新兴前沿

Federica Agnello¹, Maria Sara Mauro¹, Carla Rochira¹

¹Division of Cardiology, Azienda Ospedaliero-Universitaria Policlinico "G. Rodolico - San Marco", University of Catania, Catania, Italy.

Expert review of cardiovascular therapy

|November 23, 2023

概括

新型PCSK9抑制剂有效降低低密度脂蛋白胆固醇 (LDL-C),降低动脉样硬化心血管疾病 (ASCVD) 的风险. 单克隆抗体对高风险患者特别有希望,尽管成本和长期影响需要进一步研究.

科学领域:

心血管医学心血管医学
药理学药理学是指药理学的学科.
生物化学生物化学

背景情况:

动脉样硬化心血管疾病 (ASCVD) 是一个主要的全球健康问题,高胆固醇血症,特别是高低密度脂蛋白胆固醇 (LDL-C),作为一个关键可修改的风险因素.
蛋白转化酶亚素/素9型 (PCSK9) 在调节LDL受体水平方面发挥着关键作用,使其成为新型降脂疗法的标.

研究的目的:

审查PCSK9的结构和功能方面及其在LDL受体调节中的作用.
探索PCSK9抑制的各种药理学策略.
评估PCSK9抑制剂在管理高胆固醇血症和降低心血管风险方面的临床证据,安全性和有效性.

主要方法:

关于PCSK9结构,功能和LDL受体调节的文献综述.
探索各种PCSK9抑制策略:单克隆抗体,结合,基因沉默和活性免疫.
对临床试验数据的分析,评估与PCSK9抑制剂相关的LDL-C降低和心血管结果.

主要成果:

PCSK9抑制剂,特别是单克隆抗体,在降低LDL-C水平方面表现出显著的有效性.
临床试验证实了这些抑制剂的安全性和有效性,对他类药物不耐受和家族性高胆固醇血症患者有显著的益处.
已观察到对降低LDL-C的长期影响和对心血管结果的潜在改善.

结论:

抑制PCSK9代表了管理高胆固醇血症和降低ASCVD风险的重大进展.
单克隆抗体是一种基石疗法,为特定患者群体提供了巨大的好处.
需要进一步的研究,以解决广泛临床应用的成本效益和长期安全考虑.

关键词:

这就是为什么LDL胆固醇是LDL胆固醇.PCSK9 抑制剂的使用.其他类型:alirocumab 进化了你的生活这里是inclisiran的意思.降脂疗法是一种降脂疗法.

更多相关视频

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

相关概念视频

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...